Replacement of coagulation factors in liver or multiple organ dysfunction.
Due to the complexity of alterations in hemostasis, replacement therapy in multiple organ dysfunction is a domain for nonspecific replacement therapy by means of fresh frozen plasma. Refined methods of virus inactivation as well as the consequent declaration of the major components of plasma derivatives have led to an increasing use of high-purity blood coagulation factor concentrates. Furthermore, the problem of activated factors and their inherent thrombogenic effect is meanwhile considerably attenuated. In the future, the availability of high-purity blood coagulation factor concentrates with a defined amount and quality of their factor content will enable a specific replacement therapy in single or multiple organ dysfunction in addition to unspecific replacement therapy by fresh frozen plasma
Spannagl
M
M
Ludwig-Maximilian Universität München, Klinikum Innenstadt, Abteilung für Hämostaseologie und Transfusionsmedizin, Germany. mispannagl@t-online.edu
Schramm
W
W
D001779:Blood Coagulation Factors / Q000627:therapeutic use*; D004211:Disseminated Intravascular Coagulation / Q000175:diagnosis / Q000209:etiology; D004630:Emergencies; D006487:Hemostasis; D006801:Humans; D008107:Liver Diseases / Q000097:blood / Q000188:drug therapy* / Q000628:therapy; D009102:Multiple Organ Failure / Q000097:blood / Q000188:drug therapy* / Q000628:therapy; D010949:Plasma
D001779:Blood Coagulation Factors; C025667:prothrombin complex concentrates